Suicide risk and symptom reduction in patients assigned to placebo in duloxetine and escitalopram clinical trials: analysis of the FDA summary basis of approval reports (Q34622041)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Suicide risk and symptom reduction in patients assigned to placebo in duloxetine and escitalopram clinical trials: analysis of the FDA summary basis of approval reports |
scientific article |
Statements
1 reference
Suicide risk and symptom reduction in patients assigned to placebo in duloxetine and escitalopram clinical trials: analysis of the FDA summary basis of approval reports (English)
1 reference
Arif Khan
1 reference
Kelly Schwartz
1 reference
1 January 2007
1 reference
1 reference
19
1 reference
1
1 reference
31-36
1 reference
Identifiers
1 reference
1 reference